Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women\u27s Health Initiative by Tabung, Fred K. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Preventive and Behavioral Medicine 
Publications Population and Quantitative Health Sciences 
2016-05-24 
Association between dietary inflammatory potential and breast 
cancer incidence and death: results from the Women's Health 
Initiative 
Fred K. Tabung 
University of South Carolina - Columbia 
Et al. 
Follow this and additional works at: https://escholarship.umassmed.edu/prevbeh_pp 
 Part of the Clinical Epidemiology Commons, Dietetics and Clinical Nutrition Commons, Epidemiology 
Commons, Neoplasms Commons, and the Women's Health Commons 
Repository Citation 
Tabung FK, Steck SE, Liese AD, Zhang J, Ma Y, Caan BJ, Chlebowski RT, Freudenheim JL, Hou L, Mossavar-
Rahmani Y, Shivappa N, Vitolins MZ, Wactawski-Wende J, Ockene JK, Hebert JR. (2016). Association 
between dietary inflammatory potential and breast cancer incidence and death: results from the Women's 
Health Initiative. Preventive and Behavioral Medicine Publications. 
https://doi.org/10.1038/bjc.2016.98. Retrieved from https://escholarship.umassmed.edu/prevbeh_pp/
346 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Preventive and 
Behavioral Medicine Publications by an authorized administrator of eScholarship@UMMS. For more information, 
please contact Lisa.Palmer@umassmed.edu. 
Association between dietary inflammatory
potential and breast cancer incidence and
death: results from the Women’s Health
Initiative
Fred K Tabung1,2,3, Susan E Steck*,2,3,4, Angela D Liese2,4, Jiajia Zhang2, Yunsheng Ma5, Bette Caan6,
Rowan T Chlebowski7, Jo L Freudenheim8, Lifang Hou9, Yasmin Mossavar-Rahmani10, Nitin Shivappa2,3,
Mara Z Vitolins11, Jean Wactawski-Wende8, Judith K Ockene5 and James R He´bert2,3
1Departments of Nutrition and Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA; 2Department of
Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA; 3Cancer
Prevention and Control Program, University of South Carolina, Columbia, SC, USA; 4Center for Research in Nutrition and Health
Disparities, University of South Carolina, Columbia, SC, USA; 5Division of Preventive and Behavioral Medicine, University of
Massachusetts Medical School, Worcester, MA, USA; 6Kaiser Permanente Division of Research, Oakland, CA, USA; 7Los Angeles
Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed), Torrance, CA, USA; 8Department of Epidemiology
and Environmental Health, University at Buffalo, The State University of New York, Buffalo, NY, USA; 9Department of Preventive
Medicine and the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University,
Chicago, IL, USA; 10Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA and
11Department of Epidemiology & Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA
Background: Diet modulates inflammation and inflammatory markers have been associated with cancer outcomes. In the
Women’s Health Initiative, we investigated associations between a dietary inflammatory index (DII) and invasive breast cancer
incidence and death.
Methods: The DII was calculated from a baseline food frequency questionnaire in 122 788 postmenopausal women, enrolled from
1993 to 1998 with no prior cancer, and followed until 29 August 2014. With median follow-up of 16.02 years, there were 7495 breast
cancer cases and 667 breast cancer deaths. We used Cox regression to estimate multivariable-adjusted hazards ratios (HRs) and
95% confidence intervals (95% CIs) by DII quintiles (Q) for incidence of overall breast cancer, breast cancer subtypes, and deaths
from breast cancer. The lowest quintile (representing the most anti-inflammatory diet) was the reference.
Results: The DII was not associated with incidence of overall breast cancer (HRQ5vsQ1, 0.99; 95% CI, 0.91–1.07; Ptrend¼ 0.83 for
overall breast cancer). In a full cohort analysis, a higher risk of death from breast cancer was associated with consumption of more
pro-inflammatory diets at baseline, after controlling for multiple potential confounders (HRQ5vsQ1, 1.33; 95% CI, 1.01–1.76;
Ptrend¼ 0.03).
Conclusions: Future studies are needed to examine the inflammatory potential of post-diagnosis diet given the suggestion from
the current study that dietary inflammatory potential before diagnosis is related to breast cancer death.
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Breast cancer is the most commonly diagnosed cancer and the
second leading cause of cancer-related deaths among women in the
United States (DeSantis et al, 2014; Siegel et al, 2015). Although
there has been interest in the potential influence of dietary factors
and dietary patterns on breast cancer incidence (Terry et al, 2001;
Fung et al, 2005; Prentice et al, 2006) and survival (Chlebowski
et al, 2006; Izano et al, 2013; George et al, 2014), the findings have
been mixed. In addition, observational (Harris et al, 2003, 2011;
Hong et al, 2013) and animal intervention studies (Howe et al,
2002; Brown et al, 2008) have found associations of inflammation
with breast cancer risk, and dietary patterns have been shown to be
linked to inflammation (Esposito et al, 2004; Ma et al, 2008;
Barbaresko et al, 2013).
The recent development of a dietary inflammatory index (DII)
(Shivappa et al, 2013a) provides a new tool to evaluate diets on a
continuum from maximally anti-inflammatory to maximally pro-
inflammatory. The DII was construct validated in a variety of
studies, including the Women’s Health Initiative (WHI),
and found to predict concentrations of several inflammatory
markers (Shivappa et al, 2013b, 2015a; Tabung et al, 2015b).
Pro-inflammatory DII scores have also been consistently associated
with higher risk of colorectal cancer in previous studies (Shivappa
et al, 2014; Zamora-Ros et al, 2014; Steck et al, 2015; Wirth et al,
2015; Tabung et al, 2015a). However, two previous studies found
conflicting results for the association of the DII with breast cancer
incidence (Ge et al, 2015; Shivappa et al, 2015b). In the current
study we utilised the DII to investigate the association of the
inflammatory potential of diet with postmenopausal breast cancer
incidence and death using data from the WHI.
MATERIALS AND METHODS
Participants. The WHI was designed to address the major causes
of morbidity and mortality among postmenopausal women. The
design of the WHI has been previously described (Women’s Health
Initiative Study Group, 1998). Briefly, WHI investigators enrolled
161 808 postmenopausal women 50 to 79 years old with a
predicted43-year survival in 40 sites in the United States between
1993 and 1998. Subjects were enrolled into one or more of three
Clinical Trial (CT) groups (n¼ 68 132) or the Observational Study
(n¼ 93 676). The CT had additional eligibility criteria and women
were excluded from the Dietary Modification (DM) Trial if their
diets were reported to haveo32% energy from fat as assessed by a
food frequency questionnaire (FFQ) (Patterson et al, 1999). The
WHI protocol was approved by the institutional review boards at
the Clinical Coordinating Center (CCC) at the Fred Hutchinson
Cancer Research Center (Seattle, WA, USA) and at each of the 40
Clinical Centers (Women’s Health Initiative Study Group, 1998).
Diet assessment. During screening for the WHI, all participants
completed a standardised self-administered 122-item FFQ devel-
oped for the WHI to estimate average daily nutrient intake over the
previous 3-month period. These data served as the baseline dietary
measures. The FFQ data were considered complete if all
adjustment questions, all summary questions, 90% of the foods,
and at least one-half of every food group section was completed
(Patterson et al, 2003; Women’s Health Initiative Study Group,
1998). The nutrient database, linked to the University of Minnesota
Nutrition Data System for Research (NDSR) (Nutrition
Coordinating Center at the University of Minnesota, 2013), is
based on the US Department of Agriculture Standard Reference
Releases and manufacturer information. The WHI FFQ has
produced results comparable to those from four 24-h dietary
recall interviews and 4 days of food diaries recorded within the
WHI study population (Patterson et al, 1999).
Description of the DII. Details of the development (Shivappa
et al, 2013a) and construct validation (Shivappa et al, 2013b;
Tabung et al, 2015b) of the DII have been described elsewhere.
Briefly, an extensive literature search was performed to identify
articles published in peer-reviewed journals reporting on studies
that examined the association between dietary factors and six
inflammatory markers (interleukin (IL)-1b, IL-4, IL-6, IL-10,
tumour necrosis factor-a (TNFa), and C-reactive protein (CRP)).
A total of 1943 eligible articles published through 2010 were
indexed and scored to derive component-specific inflammatory
effect scores. In the process of reading and scoring these articles, a
total of 45 specific foods and nutrients (components of the DII)
were identified.
Actual dietary intake data derived from baseline WHI FFQ were
standardised to a representative global diet database constructed
based on 11 data sets from diverse populations in different parts of
the world. The standardised dietary intake data were then
multiplied by the literature-derived inflammatory effect scores
for each DII component, and summed across all components, to
obtain the overall DII (Shivappa et al, 2013a). A higher DII score
indicates a more inflammatory diet and a lower (i.e., more
negative) DII score indicates a less inflammatory diet. In the WHI
FFQ, 32 of the 45 original DII components were available for
inclusion in the overall DII (see Tabung et al, 2015b and Table 1
for the list of the 32 DII components included in the WHI DII
calculation). The components ginger, turmeric, garlic, oregano,
pepper, rosemary, eugenol, saffron, flavan-3-ol, flavones, flavonols,
flavonones, and anthocyanidins that are included in the original
DII calculation (Shivappa et al, 2013a) were not included in the
current study because they were not available from the WHI FFQ.
The DII has been construct validated in the WHI and found to
significantly predict concentrations of IL-6 and TNFa receptor 2
expression (Tabung et al, 2015b).
Outcome ascertainment. Outcomes included breast cancer event
(diagnosis of invasive breast cancer or confirmation of breast
cancer-related death) and time to breast cancer event. As
previously described (Curb et al, 2003), breast cancers were
initially verified by medical record and pathology report review by
physician adjudicators at each clinical centre, with final adjudica-
tion centrally by WHI cancer coders (Curb et al, 2003).
Breast cancer subtypes for analysis were defined based on
oestrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) status (Calhoun and
Collins, 2015), and combined as triple-negative (ER , PR ,
HER2 ); luminal A (ERþ and/or PRþ , HER2 ); luminal B
(ERþ and/or PRþ , HER2þ ); and ER , PR , HER2þ
subtypes (Parise and Caggiano, 2014). The histological subtypes
were defined based on Surveillance Epidemiology and End Results
program morphology codes. These included invasive ductal
carcinoma (8500/3) and invasive lobular carcinoma (8520/2).
The in situ breast cancer cases were not included.
Time-to-breast-cancer-event (diagnosis or death) was defined as
days from enrolment or randomisation until invasive breast cancer
diagnosis or confirmation of breast cancer death. Censoring time
for breast cancer incidence models was defined as days from
enrolment or randomisation until death or last contact occurring
on or before 29 August 2014 in participants without breast cancer;
for breast cancer death (fatal breast cancer) models, censoring time
was the number of days from enrolment/randomisation until last
contact occurring on or before 29 August 2014 in participants who
were still alive.
Statistical analyses. Data on 149 790 women from both the OS
and the CT were considered for the current analyses. Through 29
August 2014, 7495 women were diagnosed with invasive breast
cancer and 667 breast cancer deaths were confirmed. The following
exclusion criteria were applied to both sets of analyses: any cancer
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(except non-melanoma skin cancer) before study entry or missing
prior cancer status (n¼ 10 858), mastectomy at baseline (n¼ 268),
any cancer (except non-melanoma skin cancer) diagnosed within 2
years from baseline during follow-up (n¼ 2032), implausible
reported total energy intake values (p600 or X5000 kcal per day;
n¼ 4219) or extreme body mass index (BMI) values (o15
or450 kgm 2; n¼ 733). Participants with missing data in the
covariates listed below (n¼ 8892) were excluded, leaving a total of
122 788 participants for the current analyses. Frequencies and
percentages were used to describe the distribution of covariates
across quintiles of the DII.
We used Cox regression models to calculate hazard ratios
(HRs), associated 95% confidence intervals (95% CIs), and linear
trends for invasive breast cancer, breast cancer subtypes, breast
cancer stages, and breast cancer-related death, for DII quintiles
with adjustment for multiple covariates. The lowest DII quintile
(representing the most anti-inflammatory diet) was the referent for
all models. The analysis of breast cancer death was a full cohort
analysis of fatal breast cancer outcomes. Potential effect modifica-
tion of the association between the DII and breast cancer incidence
and death by age, BMI, regular nonsteroidal anti-inflammatory
drug (NSAID) use, and hormone use was investigated by including
DII covariate interaction terms in the Cox regression models;
none of the interaction terms was significant at Po0.10. Tests of
linear trend across DII quintiles were computed by assigning the
median value of each quintile to each participant in the quintile
and this ordinal variable was entered into models and its P-value
evaluated for significant trend.
Data on potential confounders were collected by standardised
self-administered questionnaires on demographics, medical his-
tory, and lifestyle factors. In bivariate analyses including the DII
and each of these potential confounders, a change ofX10% in the
HR comparing the univariate model with DII only with the
bivariate model resulted in inclusion of the covariate in the fully
adjusted model. Multivariable Cox regression models were
adjusted for the following covariates: age (continuous, years),
race/ethnicity (European American, African American, Hispanic,
Asian or Pacific Islander, and Other), BMI (underweight (15 to
o18.5 kgm 2), normal weight (18.5 too25 kgm 2), overweight
(25 to o30 kgm 2), and obese (30 to 50 kgm 2)); physical
activity (PA) categorised based on current public health recom-
mendations (Department of Health and Human Services, 2008), as
meeting or not meeting PA recommendations (X150min per
week of moderate intensity PA or X60min per week of vigorous
intensity PA vs o150min per week of moderate intensity PA or
o60min per week of vigorous intensity PA, respectively),
education (some high school or lower educational level, high
school graduate/some college or associate degree, X4 years of
college), family income (o$10 000, $10 000–$19 999, $20 000–
$34 999, $35 000–$49 999, $50 000–$74 999, $75 000–$99 999,
Table 1. Participant baseline characteristics (n, %) by quintiles (Q) of the dietary inflammatory index (DII)a; Women’s Health
Initiative (n¼122788); 1993–1998
Characteristic
Q1 (7.055,
o3.142) (more
anti-inflammatory
diet )
Q2
(3.142,
o2.016)
Q3
(2.016,
o0.360)
Q4
(0.360,
o1.898)
Q5 (1.898,
o5.519) (more
pro-inflammatory
diet)
Age, year (mean±s.d.) 63.5±7.1 63.5±7.1 63.2±7.2 62.8±7.1 62.3±7.2
Body mass index, (kgm2)
Underweight (15 to o18.5) 266 (1.1) 189 (0.8) 170 (0.7) 196 (0.8) 159 (0.7)
Normal weight (18.5 to o25) 10 018 (40.8) 8874 (36.1) 8297 (33.8) 7595 (30.9) 7077 (28.8)
Overweight (25 to o30) 8357 (34.0) 8605 (35.0) 8667 (35.3) 8685 (35.4) 8652 (35.2)
Obese (30 to 50) 5916 (24.1) 6891 (28.1) 7424 (30.2) 8081 (32.9) 8669 (35.3)
Race/ethnicity
Asian or Pacific Islander 1077 (4.4) 504 (2.1) 520 (2.1) 609 (2.5) 413 (1.7)
African-American 1065 (4.3) 1347 (5.5) 1743 (7.1) 2187 (8.9) 3523 (14.3)
Hispanic/Latino 495 (2.0) 589 (2.4) 847 (3.5) 940 (3.8) 1368 (5.6)
European American 21 559 (87.8) 21 793 (88.7) 21 081 (85.8) 20 484 (83.4) 18 843 (76.7)
Other 361 (1.5) 326 (1.3) 367 (1.5) 337 (1.4) 410 (1.7)
Physical activity (PA)
Not meeting PA recommendations 7890 (32.1) 10 489 (42.7) 11 643 (47.4) 12 261 (49.9) 14 483 (59.0)
Meeting PA recommendations 16 667 (67.9) 14 070 (57.3) 12 915 (52.6) 12 296 (50.1) 10 074 (41.0)
Educational level
Some high school or lower educational level 562 (2.3) 874 (3.6) 1064 (4.3) 1264 (5.1) 1874 (7.6)
High school graduate/some college or associate degree 11 337 (46.2) 13 304 (54.1) 13 819 (56.3) 13 962 (56.9) 15 308 (62.4)
X4 Years of college 12 658 (51.5) 10 381 (42.3) 9675 (39.4) 9331 (38.0) 7375 (30.0)
Smoking status
Never 12 203 (49.7) 12 501 (50.9) 12 616 (51.4) 12 457 (50.7) 12 440 (50.7)
Past 11 465 (46.7) 10 735 (43.7) 10 287 (41.9) 10 341 (42.1) 9553 (38.9)
Current 889 (3.6) 1323 (5.4) 1655 (6.7) 1759 (7.2) 2564 (10.4)
Family history of breast cancer
No 19 633 (80.0) 19 699 (80.2) 19 694 (80.2) 19 798 (80.6) 20 025 (81.5)
Yes 4924 (20.0) 4860 (19.8) 4864 (19.8) 4759 (19.4) 4532 (18.5)
NSAID use
No 9749 (39.7) 9199 (37.5) 9629 (39.2) 10 109 (41.2) 10 509 (42.8)
Yes 14 808 (60.3) 15 360 (62.5) 14 929 (60.8) 14 448 (58.8) 14 048 (57.2)
Abbreviation: NSAID¼ nonsteroidal anti-inflammatory drug.
aThe DII components available in the Women’s Health Initiative (WHI) food frequency questionnaire (FFQ) were: alcohol, b-carotene, caffeine, carbohydrates, cholesterol, total energy, total fat,
saturated fat, fiber, folic acid, iron, magnesium, niacin, riboflavin, thiamine, zinc, monounsaturated fatty acid (fa), polyunsaturated fa, omega 3 fa, omega 6 fa, trans fat, protein, selenium,
vitamins B12, B6, A, C, D, E, onion, green/black tea, and isoflavones; the following components not available in the WHI FFQ were: ginger, turmeric, garlic, oregano, rosemary, pepper, eugenol,
saffron, flavan-3-ol, flavones, flavonols, flavonones, and anthocyanidins.
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$100 000–$149 999, X$150 000), smoking status (current, past,
and never), family history of breast cancer (yes/no), mammo-
graphy use within 2 years of baseline (yes/no), age at menarche
(o10, 11–15, X16 years), number of live births (none, 1–3, X4),
oophorectomy status (no ovaries removed, one or both ovaries
removed), hormone therapy use (never, former, current), regular
(at least twice a week for the previous 2 weeks; Coghill et al, 2012)
use of NSAID (yes/no), DM arm (intervention, control, not
randomised to DM), HRT arm (oestrogen-alone intervention,
oestrogen-alone control, oestrogen and progesterone intervention,
oestrogen and progesterone control, not randomised to HRT),
calcium and vitamin D (CaD) trial arm (intervention, control, not
randomised to CaD), and total energy intake (Kcal per day). The
proportional hazards assumption was assessed for each covariate
using Martingale-based residuals. The CaD arm violated the
assumption in both the incidence and death analyses, and all Cox
regression models were thus stratified by CaD.
We conducted several sensitivity analyses; first, we excluded
women diagnosed with (n¼ 1517), or who died from (n¼ 11),
breast cancer within 3 years from baseline to reduce the likelihood
that results reflected the presence of subclinical disease at baseline
(McBride et al, 2000; Patterson et al, 2012). Second, we conducted
incidence and death analyses excluding women diagnosed with any
cancer at any time point before the diagnosis of breast cancer.
Third, we stratified by WHI study arm (OS and CT) to ensure that
results were not sensitive to the WHI study design. Finally, we
compared women with and without missing data in the covariates
included in the multivariable models to ensure that the women
excluded because of missing data were not systematically different
from the women retained for final analysis.
RESULTS
After applying all exclusion criteria, a total of 7495 cases of
incident invasive breast cancer (average 15.1 years (1 848 542.1
person-years) of follow-up) and 667 breast cancer deaths (average
16.6 years (1 672 710.1 person-years) of follow-up) were available
for analyses. The mean (±s.d.) DII score was  0.78 (±2.61), and
ranged from a maximally anti-inflammatory score of  7.06 to a
maximally pro-inflammatory score of þ 5.79. Table 1 presents the
distribution of participants’ characteristics across quintiles of the
DII. Participants consuming the most inflammatory diets (classi-
fied in the highest quintile) were more likely to be obese, African
American or Hispanic, not meeting public health recommenda-
tions for physical activity, and reported a low level of education,
compared with their counterparts who consumed more anti-
inflammatory diets (i.e., likely to fall into lower DII quintiles,
Table 1).
There was no statistically significant association between the DII
and risk of overall breast cancer incidence. In the multivariable-
adjusted model, the HR (and 95% CI) comparing women in the
highest with those in the lowest DII quintile was 0.99 (95% CI,
0.91–1.07; Table 2). There was a positive association between the
DII and overall breast cancer death in the fourth and fifth quintiles
compared with the lowest quintile of DII in the age and energy
intake-adjusted model (HRQ4vsQ1, 1.51; 95% CI, 1.18–1.94 and
HRQ5vsQ1, 1.53; 95% CI, 1.18–2.00; Ptrend, 0.0005). The association
between the DII and breast cancer death was slightly attenuated,
but persisted even after controlling for BMI, physical activity,
education, smoking status, hormone therapy use, regular NSAID
use, DM arm, and screening history (HRQ4vsQ1, 1.38; 95% CI,
1.07–1.79 and HRQ5vsQ1, 1.33; 95% CI, 1.01–1.76; Ptrend¼ 0.03;
Table 2). Both BMI and physical activity were largely responsible
for the attenuation of HRs in the multivariable-adjusted model.
The HRs in the fourth and fifth DII quintiles without adjusting for
BMI and physical activity were: HRQ4vsQ1, 1.48; 95% CI, 1.15–1.90
and HRQ5vsQ1, 1.46; 95% CI, 1.11–1.93; Ptrend¼ 0.002.
Table 3 presents HRs for the association between DII quintiles
and subtypes and stage of breast cancer. There was a tendency
towards higher risk of breast cancer subtypes that included
HER2þ (i.e., luminal B (ERþ and/or PRþ , HER2þ ) and
(ER , PR , HER2þ ) subtypes) with higher DII scores that did
not attain statistical significance. Irrespective of ER or PR status,
risk of HER2þ breast cancer subtype was significantly higher in
women in quintile 4 compared with those in quintile 1 (HR, 1.33;
95% CI, 1.05–1.67); however, risk appeared to be attenuated (and
nonsignificant) in quintile 5 (HR, 1.11; 95% CI, 0.85–1.44;
Ptrend¼ 0.24). There was no association between the DII and
localised breast cancer. However, there was a suggestion of an
inverse association between the DII and regional/distant disease
(HRQ5vsQ1, 0.84; 95% CI, 0.79–1.00; Ptrend¼ 0.03).
In sensitivity analyses (Table 4), results for overall breast cancer
incidence and breast cancer death did not materially change when
we excluded breast cancer cases and deaths that occurred within 3
years from baseline. The findings also did not change materially
when all other cancers diagnosed before breast cancer were
excluded (Supplementary Table 1). Results in the OS were not
Table 2. Hazard ratios of the association between the dietary inflammatory index (DII) and breast cancer incidence and death;
Women’s Health Initiative (n¼122788), 1993–2014
Breast cancer incidence
Q1 (7.055,
o3.142) (more
anti-inflammatory
diet)
Q2
(3.142,
o2.016)
Q3
(2.016,
o0.360)
Q4
(0.360,
o1.898)
Q5 (1.898,
5.519) (more
pro-inflammatory
diet) Ptrend
a
Breast cancer incidence, n¼7495, n (%)b 1601 (6.52%) 1538 (6.36%) 1429 (5.82%) 1522 (6.20%) 1405 (5.72%)
HR (95% CI), age- and energy-adjusted model 1.00 0.98 (0.91, 1.05) 0.91 (0.85, 0.98) 0.97 (0.90, 1.04) 0.93 (0.86, 1.00) 0.09
HR (95% CI), multivariable-adjusted modelc 1.00 0.98 (0.91, 1.05) 0.93 (0.86, 1.00) 1.00 (0.93, 1.07) 0.99 (0.91, 1.07) 0.83
Breast cancer death
Q1 (7.055,
o3.162)
Q2 (3.162,
o2.032)
Q3 (2.032,
o0.374)
Q4 (0.374,
o1.874)
Q5 (1.874,
5.519)
Breast cancer death, n¼ 667, n (%)b 108 (0.53%) 127 (0.63%) 138 (0.68%) 152 (0.75%) 142 (0.70%)
HR (95% CI), age- and energy-adjusted model 1.00 1.21 (0.94, 1.57) 1.35 (1.05, 1.74) 1.51 (1.18, 1.94) 1.53 (1.18, 2.00) 0.0005
HR (95% CI), multivariable-adjusted modelc 1.00 1.15 (0.89, 1.49) 1.25 (0.97, 1.62) 1.38 (1.07, 1.79) 1.33 (1.01, 1.76) 0.03
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; Q¼quintile.
aThe P-value for trend was obtained by assigning the median value of each DII quintile to all participants in each quintile.
bThe proportion of breast cancer events (cases or deaths) in the quintile.
cAdjusted for age, energy intake, race/ethnicity, income, education, smoking status, mammography within 2 years of baseline, age at menarche, number of live births, oophorectomy status,
hormone therapy use, nonsteroidal anti-inflammatory drug (NSAID) use, dietary modification trial arm, hormone therapy trial arm, body mass index, and physical activity. Calcium and vitamin D
(CaD) trial arm violated the proportional hazards assumption and all multivariable-adjusted models were stratified by CaD.
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materially different than in the CT when stratified by WHI study
participation (data not shown). Comparing demographic and other
characteristics of women who were excluded because of missing
data vs those included in the analyses did not reveal substantial
differences between these two populations (data not shown).
DISCUSSION
In this large prospective investigation of pre-diagnosis dietary
inflammatory potential in postmenopausal women, a more
pro-inflammatory diet was not associated with higher risk of
overall breast cancer incidence. However, there was a significantly
higher risk of breast cancer death with higher baseline DII
scores in a full cohort analysis. In subgroup analyses, higher DII
was also associated with a higher risk of HER2þ breast cancer in
the fourth quintile of DII score, but not in the fifth (highest)
quintile.
Similar to our finding, most prospective observational studies
(Smith-Warner et al, 2001; Terry et al, 2001; Adebamowo et al,
2005; Fung et al, 2005) and clinical trials (Prentice et al, 2006) have
not found a significant association between higher diet quality as
assessed by other dietary patterns and overall breast cancer risk.
Diet quality is inversely related to the inflammatory potential of
diet, that is, higher quality diets would have lower DII scores
(Wirth et al, 2016). In the WHI-DM Trial, where a low-fat dietary
pattern was assessed, after 9.1 years of follow up, there appeared to
be fewer invasive breast cancers in the dietary intervention group.
However, the difference was not statistically significant (HR, 0.91;
95% CI, 0.83–1.01) (Prentice et al, 2006). A prospective study
examining the association of several diet quality scores, including
the Healthy Eating Index, Alternate Healthy Eating Index, Diet
Quality Index-Revised, and Recommended Food Score (the sum of
23 recommended food items consumed at least weekly), did not
find a significant association with overall breast cancer risk, though
risk of ER-negative tumours was lower with higher Recommended
Food Scores (Fung et al, 2006).
Two studies have found conflicting results of the association
between the DII and breast cancer incidence. A case–control study
from Germany found no association (Ge et al, 2015), whereas a
prospective cohort study in Sweden reported a positive association
Table 3. Risk of breast cancer by subtype and stage at diagnosis, across quintiles of the dietary inflammatory index (DII);
Women’s Health Initiative (n¼122788), 1993–2014
Referent
Q1
(7.055,o3.145)
(more anti-
inflammatory diet )
Q2 (3.145,
o2.026)
Q3 (2.026,
o0.377)
Q4 (0.377,
o1.884)
Q5 (1.884,
o5.789)
(more pro-
inflammatory
diet) Ptrend
a
Molecular subtypes
ERþ ; n¼ 5943 cases, n (%)b 1288 (5.30%) 1225 (5.05%) 1138 (4.69%) 1210 (4.99%) 1082 (4.46%)
HR (95% CI) 1.00 0.97 (0.90, 1.05) 0.93 (0.85, 1.00) 1.00 (0.92, 1.08) 0.97 (0.89, 1.06) 0.88
ER ; n¼ 1025 cases, n (%) 198 (0.86%) 212 (0.91%) 190 (0.81%) 214 (0.92%) 211 (0.90%)
HR (95%CI) 1.00 1.09 (0.90, 1.33) 0.98 (0.80, 1.21) 1.11 (0.91, 1.36) 1.13 (0.91, 1.41) 0.27
PRþ ; n¼ 5001 cases, n (%) 1067 (4.44%) 1028 (4.27%) 966 (4.01%) 1041 (4.32%) 899 (3.74%)
HR (95%CI) 1.00 0.99 (0.90, 1.08) 0.95 (0.87, 1.04) 1.03 (0.95, 1.13) 0.98 (0.89, 1.08) 0.84
PR ; n¼ 1859 cases, n (%) 398 (1.70%) 377 (1.61%) 344 (1.47%) 372 (1.59%) 368 (1.56%)
HR (95%CI) 1.00 0.97 (0.84, 1.12) 0.90 (0.78, 1.05) 0.98 (0.85, 1.14) 1.03 (0.87, 1.20) 0.60
HER2þ ; n¼ 771 cases, n (%) 139 (0.60%) 151 (0.65%) 163 (0.70%) 178 (0.77%) 140 (0.60%)
HR (95% CI) 1.00 1.11 (0.88, 1.40) 1.21 (0.96, 1.52) 1.33 (1.05, 1.67) 1.11 (0.85, 1.44) 0.24
HER2 ; n¼ 4731 cases, n (%) 1039 (4.33%) 953 (3.98%) 895 (3.73%) 956 (3.98%) 888 (3.69%)
HR (95% CI) 1.00 0.94 (0.86, 1.02) 0.90 (0.82, 0.98) 0.96 (0.88, 1.05) 0.96 (0.87, 1.07) 0.91
ER , PR , HER2þ ; n¼205 cases, n (%) 35 (0.15%) 34 (0.15%) 47 (0.20%) 45 (0.19%) 44 (0.19%)
HR (95% CI) 1.00 1.02 (0.63, 1.65) 1.41 (0.90, 2.21) 1.36 (0.86, 2.15) 1.42 (0.86, 2.34) 0.11
Luminal A (ERþ and/or PRþ , HER2 ); n¼4202 cases, n (%) 935 (3.91%) 840 (3.52%) 802 (3.35%) 848 (3.55%) 777 (3.25%)
HR (95% CI) 1.00 0.92 (0.83, 1.01) 0.89 (0.81, 0.98) 0.95 (0.86, 1.05) 0.94 (0.85, 1.05) 0.67
Luminal B (ERþ and/or PRþ , HER2þ ); n¼554 cases, n (%) 104 (0.45%) 115 (0.50%) 113 (0.49%) 128 (0.55%) 94 (0.40%)
HR (95% CI) 1.00 1.11 (0.84, 1.45) 1.10 (0.83, 1.44) 1.25 (0.96, 1.63) 0.96 (0.70, 1.30) 0.96
Triple negative (ER , PR , HER2 ); n¼ 509 cases, n (%) 99 (0.43%) 109 (0.47%) 90 (0.39%) 104 (0.45%) 107 (0.46%)
HR (95% CI) 1.00 1.12 (0.85, 1.48) 0.93 (0.69, 1.24) 1.06 (0.80, 1.42) 1.11 (0.82, 1.51) 0.60
Histologic subtypes
Invasive ductal carcinoma; n¼4767 cases, n (%) 1007 (4.20%) 998 (4.16%) 917 (3.81%) 962 (4.01%) 883 (3.67%)
HR (95% CI) 1.00 1.00 (0.92, 1.09) 0.93 (0.85, 1.02) 0.98 (0.89, 1.07) 0.94 (0.85, 1.04) 0.26
Invasive lobular carcinoma; n¼758 cases, n (%) 172 (0.74%) 151 (0.65%) 139 (0.60%) 153 (0.66%) 143 (0.61%)
HR (95% CI) 1.00 0.91 (0.73, 1.14) 0.87 (0.69, 1.09) 0.98 (0.78, 1.23) 1.01 (0.79, 1.30) 0.65
Stage at diagnosis
Localised; n¼5567 cases 1217 (5.03%) 1054 (4.77%) 1036 (4.29%) 1141 (4.72%) 1019 (4.22%)
1.00 0.94 (0.86, 1.02) 0.99 (0.91, 1.08) 0.99 (0.91, 1.08) 1.00 (0.88, 1.06) 0.97
Regional/distant; n¼1799 cases 363 (1.56%) 361 (1.54%) 369 (1.57%) 351 (1.50%) 355 (1.51%)
1.00 1.01 (0.87, 1.17) 0.98 (0.85, 1.15) 0.97 (0.83, 1.13) 0.84 (0.79, 1.00) 0.03
Abbreviations: CI¼ confidence interval; ER¼oestrogen receptor; HER2¼ human epidermal growth factor receptor 2; HR¼ hazard ratio; PR¼progesterone receptor; Q¼quintile. All models
were adjusted for age, race/ethnicity, income, education, body mass index, physical activity, smoking status, mammography within 2 years of baseline, age at menarche, number of live births,
oophorectomy status, hormone therapy use, nonsteroidal anti-inflammatory drug (NSAID) use, dietary modification trial arm, hormone therapy trial arm, and energy intake. Calcium and vitamin
D (CaD) trial arm violated the proportional hazards assumption and all multivariable-adjusted models were stratified by CaD. Case frequencies were obtained after excluding participants with
missing data in the covariates.
aThe P-value for trend was obtained by assigning the median value of each DII quintile to all participants in the quintile.
bThe proportion of breast cancer events (cases or deaths) in each quintile.
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(Shivappa et al, 2015b) between higher DII scores and risk of breast
cancer. Our study of postmenopausal American women may differ
from these two previous studies because of differences in dietary
inflammatory potential of the study populations. The mean
(±s.d.) DII scores in the Swedish (2.67±1.47) and German
(0.85±1.30) studies were more pro-inflammatory compared with
the current study ( 0.78±2.61).
It is possible that diet may differentially influence breast cancer
development based on the cancer phenotype. Similar to our
differential findings by HER2 subtypes, another prospective study,
in Italy, found an association between higher consumption of salad
vegetables and lower risk of HER2þ breast cancer, and a
suggestion of higher risk of HER2 breast cancer with more
prudent dietary patterns (Sant et al, 2007). The WHI low-fat
intervention trial investigated breast cancer risk by tumour
characteristics including hormone receptor status. The HR
estimate was not related to ER status, but was lower for PR-
negative tumours than for PR-positive tumours (P¼ 0.04). When
tumours were classified by both ER and PR status, there was an
indication (P¼ 0.04) of HR variation with stronger evidence for a
reduction in the occurrence of tumours that were ER positive and
PR negative. The HER2 status was not available for breast cancers
diagnosed early in that trial and was therefore not investigated
(Prentice et al, 2006). Overall, findings from this previous study of
the WHI-DM provide further support for a potential differential
role of diet on breast cancer risk by cancer phenotype. Given the
lack of dose response, and smaller number of HER2þ cases in the
current study, future studies examining association between diet
quality and breast cancer phenotypes are warranted. Similarly, the
suggestion of an inverse trend between the DII and risk of regional/
distant breast cancer was unexpected as there is no precedent for a
similar result in the literature.
Our result of higher risk of breast cancer death with higher
consumption of pro-inflammatory diets is similar to the finding by
Mai et al (2005), who observed a moderate association between
pre-diagnosis diet and risk of breast cancer death. They found a
25% lower risk of breast cancer-related death (HR, 0.75; 95% CI,
0.56–1.00; Ptrend¼ 0.06) for women in the highest quartile
compared with the lowest quartile of Recommended Food Score
after adjusting for potential confounding factors (Mai et al, 2005).
The potential role of chronic inflammation in breast cancer death
is supported by evidence from studies on the association between
inflammatory markers and breast cancer mortality. Higher
concentrations of most inflammatory markers including CRP,
IL-6, and TNFa have been associated with higher risk of breast
cancer mortality (Benoy et al, 2004; Heike and Rainer, 2007;
Goldberg and Schwertfeger, 2010).
The attenuated association between higher DII scores and breast
cancer death when we additionally adjusted for BMI and physical
activity may partially be because of confounding by these two
energy-balance covariates. Obesity or weight gain has been
associated with the quality of dietary intake (Fung et al, 2015)
and with breast cancer prognosis (Chan et al, 2014;
Widschwendter et al, 2015). However, it is also possible that
obesity, a state of low-grade chronic inflammation (Trayhurn and
Wood, 2004; Lee et al, 2013), may partly mediate this association.
Evidence for mediation is strengthened by findings from well-
designed meta-analyses that combine data from prospective studies
of dietary determinants of long-term weight gain, and randomised
clinical trials evaluating short-term effects of specific dietary factors
on weight changes (Malik et al, 2006; Hu, 2013; Pan et al, 2013).
Therefore, the risk of breast cancer death from consuming
highly pro-inflammatory diets is likely higher than the 33%
(comparing extreme DII quintiles) we obtained after additional
adjustment for BMI and physical activity. Future studies are
needed to examine the inflammatory potential of post-diagnosis
diet given the suggestion from the current study that dietary
inflammatory potential before diagnosis is related to breast cancer
death.
The study strengths include the use of the DII specifically
designed to assess the inflammatory potential of diet; a large, well-
characterised study population; a long follow-up period; and
central adjudication of breast cancer outcomes. We conducted
several sensitivity analyses, including the investigation of the
possibility that early malignant lesions might have affected the
dietary intake or the report thereof by excluding participants who
were diagnosed with invasive breast cancer or who died from it
within 3 years from baseline (McBride et al, 2000; Patterson et al,
2012), and our findings were unchanged (Table 4).
Study limitations include known measurement error in using an
FFQ for diet assessment (Hebert et al, 2002; He´bert et al, 2014) and
the use of a single FFQ at one time point (baseline) only, though
diet could change during follow-up. We adjusted for study arm in
the multivariable models and investigated the longitudinal stability
Table 4. Hazard ratios of the association between the dietary inflammatory index (DII) and breast cancer incidence and death,
with the exclusion of breast cancer cases and deaths that occurred within 3 years from baseline; Women’s Health Initiative
(n¼122788), 1993–2014
Breast cancer incidence
Q1 (7.055,
o3.145)
(more anti-
inflammatory
diet )
Q2 (3.145,
o2.026)
Q3 (2.026,
o0.377)
Q4 (0.377,
o1.884)
Q5 (1.884,
o5.789)
(more pro-
inflammatory
diet) Ptrend
a
Breast cancer incidence, n¼5978, n (%)b 1264 (5.25%) 1221 (5.07%) 1118 (4.64%) 1228 (5.09%) 1147 (4.76%)
HR (95% CI), age- and energy-adjusted model 1.00 0.99 (0.91, 1.07) 0.91 (0.84, 0.98) 0.99 (0.92, 1.08) 0.98 (0.89, 1.05) 0.71
HR (95% CI), multivariable-adjusted modelc 1.00 0.99 (0.91, 1.07) 0.92 (0.85, 1.00) 1.01 (0.93, 1.10) 1.02 (0.93, 1.12) 0.31
Breast cancer death
Q1 (7.055,
o3.165)
Q2 (3.165,
o2.040)
Q3 (2.040,
o0.3889)
Q4 (0.3889,
o1.863)
Q5 (1.863,
5.789)
Breast cancer death, n¼ 656, n (%)b 105 (0.52%) 124 (0.61%) 137 (0.68%) 152 (0.75%) 138 (0.68)
HR (95% CI), age- and energy-adjusted model 1.00 1.21 (0.94, 1.58) 1.38 (1.07, 1.78) 1.56 (1.21, 2.00) 1.54 (1.18, 2.02) 0.0004
HR (95% CI), multivariable-adjusted modelc 1.00 1.16 (0.89, 1.51) 1.28 (0.99, 1.66) 1.43 (1.10, 1.85) 1.34 (1.01, 1.79) 0.02
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; Q¼quintile.
aThe P-value for trend was obtained by assigning the median value of each DII quintile to all participants in each quintile.
bThe proportion of breast cancer events (cases or deaths) in the quintile.
cAdjusted for age, energy intake, race/ethnicity, income, education, smoking status, mammography within 2 years of baseline, age at menarche, number of live births, oophorectomy status,
hormone therapy use, nonsteroidal anti-inflammatory drug (NSAID) use, dietary modification trial arm, hormone therapy trial arm, body mass index, and physical activity. Calcium and vitamin D
(CaD) trial arm violated the proportional hazards assumption and all multivariable-adjusted models were stratified by CaD.
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of DII scores in the WHI-OS and DM control arm participants in a
separate study and found DII scores not to change significantly
over time (Tabung et al, 2015a, b, and unpublished results). In
addition, 13 dietary components of the DII were missing from the
WHI FFQ, and all 13 of these missing items are anti-inflammatory.
Thus, the DII may have a lower predictive ability in this
predominantly White and highly educated study population with
a more healthful diet consuming food items not on the WHI FFQ
list. It is important to note, though, that in the construct validation
of the DII in the WHI, the DII computed based on the 32
components available in the WHI FFQ predicted concentrations of
inflammatory markers (Tabung et al, 2015b). The DII score
calculated from the 32 available components ranged from  7.1 to
þ 5.8, which is higher than the range of  5.4 to þ 5.8 obtained in
the first DII construct validation study using data from fifteen 24-h
dietary recalls with 44 of the 45 DII components (Shivappa et al,
2013b), indicating that the range of DII may be more dependent on
the amount of foods actually consumed rather than on the number
of available components. Missing data in all covariates included in
the multivariable models could potentially bias our HR estimates;
however, the women excluded because of missing data were similar
to those retained on all characteristics included in Table 1. In
addition, when we excluded major contributors of missing data
such as family history of breast cancer and NSAID use, there were
no material differences in HR estimates (data not shown). Although
we adjusted for a large number of potential confounders, there may
still exist potential residual or unmeasured confounding. In addition,
given the number of tests in Table 3, we cannot rule out that our
findings for HER2þ subtype or regional/distant disease are because
of chance, though all tests were pre-determined.
Data on treatment were not available, although we did not
expect treatment to have an impact on these analyses related to
baseline diet estimated well before a breast cancer diagnosis. In the
death analyses, we adjusted for race/ethnicity, physical activity, and
education, among other potential confounders, but did not adjust
for stage (and other tumour characteristics) because stage is more
likely a mediator or modifier than a confounder of the association
between baseline pre-diagnosis diet and breast cancer death.
However, stage may confound the association between post-
diagnosis diet and survival from breast cancer, as patients may be
advised or choose to eat differently based on tumour characteristics
or treatment options (that are often based on tumour character-
istics). Post-diagnosis diet was not available for all WHI subjects
diagnosed with cancer and, therefore, was not examined in the
current analyses.
CONCLUSION
In this large prospective study of postmenopausal women, a diet
characterised by high inflammatory potential, as indicated by
higher DII scores, was associated with higher risk of breast cancer
death but not incidence of overall breast cancer. Our findings
suggest that lowering the inflammatory potential of a woman’s diet
may be a potential means for reducing the risk of breast cancer
death. Future studies should explore whether dietary intervention
focused on inflammation could affect the risk of dying from breast
cancer.
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